Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer

Stage IV Renal Cell Cancer Clinical Trial

Official title:

A Phase II Randomized Discontinuation Trial Of Carboxyaminoimidazole (CAI, NSC 609974) In Metastatic Renal Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00006486
• Other study ID #: NCI-2012-02364
• Secondary ID: CLB-69901U10CA03
• Status: Completed
• Phase: Phase 2
• First received: November 6, 2000
• Last updated: January 15, 2013
• Start date: October 2000

Study information

• Verified date: January 2013
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Randomized phase II trial to study the effectiveness of carboxyamidotriazole in treating patients who have metastatic kidney cancer. Carboxyamidotriazole may stop the growth of kidney cancer by stopping blood flow to the tumor

Description:

OBJECTIVES:

I. Determine the toxicity and disease-stabilizing effect of carboxyamidotriazole in patients with metastatic renal cell carcinoma.

II. Determine the objective response rate in patients treated with this drug.

OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified according to time from diagnosis of metastatic disease to study entry (fewer than 24 months vs 24 months or more).

Patients receive oral carboxyamidotriazole (CAI) daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.

Patients with stable disease are randomized to one of two treatment arms.

Arm I: Patients receive oral CAI as above.

Arm II: Patients receive a placebo.

Treatment repeats every 4 weeks for at least 4 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression are unblinded and those on placebo begin oral CAI as above.

Patients are followed every 6 months.

PROJECTED ACCRUAL: A maximum of 335 patients will be accrued for this study within 15-25 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 335
• Est. primary completion date: October 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed renal cell carcinoma

• Metastatic or unresectable disease

• Documented disease progression, even after nephrectomy

• At least 1 unidimensionally measurable lesion

• At least 20 mm by conventional techniques

• At least 10 mm by spiral CT scan

• The following lesions are not considered measurable:

• Bone lesions

• Leptomeningeal disease

• Ascites

• Pleural/pericardial effusion

• Abdominal masses not confirmed and followed by imaging

• Cystic lesions

• Performance status - CTC 0-2

• WBC at least 2,000/mm^3

• Platelet count at least 75,000/mm^3

• Bilirubin no greater than upper limit of normal (ULN)

• AST no greater than 2.5 times ULN

• Creatinine no greater than 2.0 mg/dL

• Not pregnant or nursing

• Fertile patients must use effective contraception

• No baseline neuropathy or cerebellar dysfunction greater than grade 1

• At least 4 weeks since prior immunotherapy

• No prior carboxyamidotriazole

• No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)

• Concurrent epoetin alfa allowed

• At least 4 weeks since prior chemotherapy

• No concurrent chemotherapy

• No concurrent hormonal therapy except steroids for adrenal failure or hormones for conditions not related to disease (e.g., insulin for diabetes)

• At least 4 weeks since prior radiotherapy

• No concurrent palliative radiotherapy

• See Disease Characteristics

• At least 4 weeks since prior surgery

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Recurrent Renal Cell Cancer
• Stage IV Renal Cell Cancer

Intervention

Drug:
• carboxyamidotriazole
Given orally

Other:
• placebo
Given orally

Locations

Country	Name	City	State
United States	Cancer and Leukemia Group B	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients progressing on placebo to the proportion progressing on CAI		Up to 16 weeks	No
Primary	Proportions of patients with stable disease		Up to 16 weeks	No
Primary	Objective response		Up to 16 weeks	No